Insider Buying: Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Purchases 18,900 Shares of Stock

Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Andrew Warwick Hamer acquired 18,900 shares of the business’s stock in a transaction dated Thursday, December 19th. The shares were acquired at an average cost of C$1.88 per share, with a total value of C$35,606.69.

Cardiol Therapeutics Price Performance

Shares of CRDL stock remained flat at C$1.80 during trading hours on Tuesday. The stock had a trading volume of 7,700 shares, compared to its average volume of 134,125. Cardiol Therapeutics Inc. has a 12-month low of C$1.09 and a 12-month high of C$4.26. The stock has a market cap of C$125.78 million, a P/E ratio of -4.09 and a beta of 0.70. The stock’s 50-day moving average price is C$2.36 and its 200-day moving average price is C$2.68. The company has a debt-to-equity ratio of 1.07, a quick ratio of 6.84 and a current ratio of 2.39.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.